The Uromigos chat with Axel Merseburger about his paper on continuing enzalutamide with docetaxel for the treatment of CRPC. Rob Jones discusses the current state of PARP inhibition in prostate cancer as well as differing opinions on the treatment. Silke Gillessen and Nick James discuss a randomized trial on duration of adjuvant/salvage androgen ablation with XRT. Alex Wyatt joins The Uromigos to answer questions about ctDNA in prostate cancer and discuss his latest paper on that topic. Declan Murphy and Matt Cooperberg debate the use of interventions in active surveillance for patients with prostate cancer. Dr. Oliver Sartor, medical director of Tulane Cancer Center, discusses his career development and work in prostate cancer. Neal Shore describes his recent controversial paper and the over-treatment of patients with low-grade disease. Phillip Kuo discusses phase 3 of the VISION trial that utilizes Lutetium-177 for the treatment of prostate cancer. Drs. Rana McKay and Kim Chi question whether doublet or triplet therapy is appropriate in the first-line. Martin Stockler describes the ENZAMET trial, which shows mixed effects of enza on QOL in prostate cancer. Dr. Stefano Fanti focuses on PSMA therapy PET CT, particularly when to use this as a diagnostic. Dr. Fred Saad describes the results of the PROpel Phase III trial. Kim Chi, MD, describes the results of the MAGNITUDE trial, Results from the ARASENS trial appear to have confirmed triple therapy as the new standard of care for mHSPC. Pete Nelson, MD, describes mechanism of action and current clinical application in prostate cancer. Silke Gillessen and Chris Sweeney join Tom and Brian to give a year in review. Dr. Tanya Dorff discusses the TALAPRO-1 study and the role of PARP inhibitors in prostate cancer. Dr. Karim Fizazi summarizes PEACE-1 data and describes the OS benefit of the triplet. Dr. Gert Attard describes the practice-changing plenary data from the STAMPEDE study, presented at ESMO 2021. Dr. Neeraj Agarwal describes the COSMIC-21 study on cabozantinib and atezolizumab in prostate cancer patients.